Stockscreener 앱 받기
15.10
3.35%
0.49
시간 외 거래:
15.01
-0.09
-0.60%
Cadrenal Therapeutics Inc 주식(CVKD)의 최신 뉴스
Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025 - BioSpace
(CVKD) Technical Pivots with Risk Controls - news.stocktradersdaily.com
What is Zacks Small Cap’s Estimate for CVKD FY2025 Earnings? - Defense World
CVKD: Preparations Continue for Phase 3 Trial of Tecarfarin… - MSN
CVKD: Preparations Continue for Phase 3 Trial of Tecarfarin - Research Tree
Cadrenal Therapeutics (NASDAQ:CVKD) Earns Buy Rating from HC Wainwright - Defense World
(CVKD) Proactive Strategies - news.stocktradersdaily.com
Positive Outlook for Cadrenal Therapeutics, Inc. Amid Strategic Developments and FDA Trial Milestone - TipRanks
Cadrenal Therapeutics (CVKD) Receives Buy Rating from HC Wainwright & Co. | CVKD Stock News - GuruFocus
Cadrenal Therapeutics advances in tecarfarin production By Investing.com - Investing.com Nigeria
Cadrenal Therapeutics advances in tecarfarin production - Investing.com
Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness - Business Wire
Cadrenal Therapeutics, Inc. Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness - marketscreener.com
Cadrenal Therapeutics Reports Increased Losses Amid R&D Expansion - TipRanks
$34 Billion Market in 2025 Advancing to $45 Billion in 2026 forNORTHEAST - NORTHEAST - NEWS CHANNEL NEBRASKA
$34 Billion Market in 2025 Advancing to $45 Billion in 2026 - openPR.com
Shares Of This EV Stock Soar On Year-Over-Year Guidance - The Globe and Mail
$34 Billion Market in 2025 Advancing to $45 Billion in 2026 for Phase III Development of New Blood Thiner, Less Problematic Than Warfrain: Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) - The Globe and Mail
$34 Billion Market in 2025 Advancing to $45 Billion in 2026 for Phase III Development of New Blood Thiner, Less Problematic Than Warfrain: Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) | FinancialContent - FinancialContent
$34 Billion Market in 2025 Advancing to $45 Billion in 2026 for Phase III Development of New Blood Thinner, Less Problematic Than Warfrain: $CVKD | FinancialContent - FinancialContent
Cisco Expands Partnership with Saudi Arabia to Power the AI Future - The Globe and Mail
Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update - BioSpace
CADRENAL THERAPEUTICS Earnings Preview: Recent $CVKD Insider Trading, Hedge Fund Activity, and More - Nasdaq
10,554 Shares in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Purchased by Geode Capital Management LLC - Defense World
Cadrenal Therapeutics (CVKD) to Release Quarterly Earnings on Thursday - Defense World
Sprott Asset Management buying more Sprott Phys. Copper Trust (COP) - The Globe and Mail
Cadrenal Therapeutics (NASDAQ:CVKD) Shares Up 0.8% – Here’s Why - Defense World
Trading (CVKD) With Integrated Risk Controls - news.stocktradersdaily.com
Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq - BioSpace
Cadrenal Therapeutics Reveals Latest Phase 3 Anticoagulant Progress at Exclusive Nasdaq Conference - Stock Titan
Cadrenal Therapeutics IncFiles Prospectus Supplement For $2.17 Million ATM Offering - marketscreener.com
Is Cadrenal Therapeutics (NASDAQ:CVKD) In A Good Position To Deliver On Growth Plans? - Yahoo
When (CVKD) Moves Investors should Listen - news.stocktradersdaily.com
Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences - BioSpace
Cadrenal Takes Center Stage: Key Executives to Showcase Novel Anticoagulant at Industry-Leading Events - Stock Titan
Q1 Earnings Estimate for CVKD Issued By Zacks Small Cap - Defense World
(CVKD) Trading Advice - Stock Traders Daily
Altimmune to put its incretin into addiction trials; Tarsus aims to raise $125M - Endpoints News
Cadrenal Therapeutics Advances Tecarfarin Development in 2024 - TipRanks
Cadrenal Therapeutics Reports Full Year 2024 Results - TradingView
Cadrenal Therapeutics, Inc. SEC 10-K Report - TradingView
Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin - Bluefield Daily Telegraph
Cadrenal Secures FDA Orphan Drug Status and Abbott Partnership for Breakthrough Phase 3 Trial - StockTitan
CVKD: Collaborating with Abbott for Pivotal Phase 3 Trial - Research Tree
Cadrenal and Abbott sign agreement for LVAD trial of tecarfarin - Yahoo Finance
Cadrenal Therapeutics teams with Abbott inTECH-LVAD trial - TipRanks
Abbott Laboratories (NYSE:ABT) Partners With Cadrenal Therapeutics For TECH-LVAD Trial In Growing US$2B LVAD Market - Yahoo Finance
Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD - BioSpace
Cadrenal Therapeutics to Collaborate With Abbott on Trial of Heart Device Drug -March 04, 2025 at 08:53 am EST - Marketscreener.com
Cadrenal Therapeutics Announces Collaboration Agreement With Abbott -March 04, 2025 at 08:14 am EST - Marketscreener.com
Cadrenal Therapeutics (CVKD) Projected to Post Earnings on Monday - The AM Reporter
Cadrenal Therapeutics (CVKD) Expected to Announce Earnings on Monday - Defense World
CVKD stock hits 52-week high at $20.79 amid robust growth By Investing.com - Investing.com South Africa
CVKD stock hits 52-week high at $20.79 amid robust growth - Investing.com India
1.21%
1.51%
자본화:
|
볼륨(24시간):